Ascelia Pharma AB (OSTO:ACE) Accumulated Depreciation: kr0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ACE Ascelia Pharma AB OSTO:ACE
17 GF Score
Price kr0.63
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Accumulated Depreciation?

Ascelia Pharma AB OSTO:ACE +3.79% 17 Accumulated Depreciation is kr0.00 Mil as of Jun. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Ascelia Pharma AB's quarterly accumulated depreciation declined from Dec. 2025 (kr-5.17 Mil) to Mar. 2026 (kr0.00 Mil) but then stayed the same from Mar. 2026 (kr0.00 Mil) to Jun. 2026 (kr0.00 Mil).

Ascelia Pharma AB's annual accumulated depreciation increased from Dec. 2023 (kr-3.58 Mil) to Dec. 2024 (kr-4.52 Mil) and increased from Dec. 2024 (kr-4.52 Mil) to Dec. 2025 (kr-5.17 Mil).

Ascelia Pharma AB Accumulated Depreciation Related Terms

Ascelia Pharma AB Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Accumulated Depreciation Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only -2.10 -2.70 -3.58 -4.52 -5.17

Ascelia Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -5.17 0.00 0.00
OSTO:ACE
17GF Score
Ascelia Pharma AB OSTO:ACE
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of kr0.00 Mil mean?
Ascelia Pharma AB (OSTO:ACE) has a Accumulated Depreciation of kr0.00 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Accumulated Depreciation too high?
Ascelia Pharma AB's current Accumulated Depreciation is kr0.00 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Accumulated Depreciation compare to VRTX and REGN?
Ascelia Pharma AB's Accumulated Depreciation of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Accumulated Depreciation is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Accumulated Depreciation of kr0.00 Mil. The current Accumulated Depreciation is kr0.00 Mil. Ascelia Pharma AB's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Accumulated Depreciation is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
17GF Score

Get the complete analysis for OSTO:ACE

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.63
Price